<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00852579</url>
  </required_header>
  <id_info>
    <org_study_id>AR010</org_study_id>
    <secondary_id>EUDRACT 2008-007240-34</secondary_id>
    <secondary_id>MRC Grant G0701626</secondary_id>
    <secondary_id>NRES 09/S0703/23</secondary_id>
    <nct_id>NCT00852579</nct_id>
  </id_info>
  <brief_title>Effects of Macrolides on Asthma Control</brief_title>
  <official_title>Effects of Macrolides on Asthma Control, Airway Inflammation and Bacterial Colonisation in Smokers With Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Euan J Cameron</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Glasgow</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Greater Glasgow and Clyde</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Glasgow</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthma is a common disease in Westernised societies, affecting up to 10% of the population.&#xD;
      Corticosteroids are the most effective treatment for asthma but the therapeutic response&#xD;
      varies considerably between individuals. A major cause of corticosteroid insensitivity in&#xD;
      asthma is cigarette smoking. Active cigarette smoking occurs in over 25% of adults with&#xD;
      asthma and a further 25% are ex-smokers. In a series of proof of concept clinical studies the&#xD;
      investigators demonstrated for the first time that the efficacy of inhaled and oral&#xD;
      corticosteroids is markedly impaired in smokers with asthma and to a lesser extent in&#xD;
      ex-smokers with asthma. Active cigarette smoking has other detrimental effects on asthma&#xD;
      morbidity including more severe symptoms, increased rates of hospitalisation, and accelerated&#xD;
      decline in lung function. Smoking cessation advice is often ineffective because many adult&#xD;
      smokers with asthma do not believe that they are personally at risk from their smoking, take&#xD;
      many years until stopping smoking and frequently restart smoking after quitting. Alternative&#xD;
      or additional drugs to corticosteroids are needed for smokers with asthma who are unable to&#xD;
      obtain the clinical benefits associated with stopping smoking. In a proof of concept clinical&#xD;
      trial the investigators will test the hypothesis that macrolides improve asthma control and&#xD;
      reduce sputum neutrophil counts of smokers with chronic asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak expiratory flow rate.</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma control score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average of last 7 days PEF measurements</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sputum cell counts</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of expired nitric oxide</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Airway responsiveness to methacholine</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation rates</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diary symptom score</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Daily dose 250mg</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of asthma&#xD;
&#xD;
          -  Age 18-70&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Duration of symptoms &gt;1yr with stability for 4 weeks&#xD;
&#xD;
          -  Able to maintain asthma without exacerbations during run in period&#xD;
&#xD;
          -  Able to wean off other asthma medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ex-smokers or never smokers&#xD;
&#xD;
          -  Planning to quit smoking during duration of trial&#xD;
&#xD;
          -  Patients with unstable asthma&#xD;
&#xD;
          -  Patients with current epilepsy, psychosis or history of significant atrial or&#xD;
             ventricular tachyarrhythmia&#xD;
&#xD;
          -  Corrected QT-interval greater than 450msec in women, 430msec in men&#xD;
&#xD;
          -  Low potassium levels. If can be corrected then screening can continue with&#xD;
             confirmation of normal levels prior to taking study medication&#xD;
&#xD;
          -  Liver disease (ALT and/or AST levels 2 or more times ULN)&#xD;
&#xD;
          -  Significant renal disease (Creatinine or urea levels 2 or more times ULN)&#xD;
&#xD;
          -  Any previous severe adverse reactions to macrolides&#xD;
&#xD;
          -  Patients who are known to have specific IgE sensitivity or skin test positivity to&#xD;
             grass pollen and a history of worsening of asthma due to hay fever will not be&#xD;
             recruited from mid May to the end of July&#xD;
&#xD;
          -  Upper or lower respiratory tract infection in the 4 weeks prior to randomisation. Run&#xD;
             in period can be prolonged in this situation to have 4 weeks with no respiratory&#xD;
             infection prior to randomisation.&#xD;
&#xD;
          -  Patients who require medications known to interact with azithromycin&#xD;
&#xD;
          -  On other immunosuppressants or chronic antibiotics&#xD;
&#xD;
          -  Weight less than 45kg&#xD;
&#xD;
          -  Frequent asthma exacerbations (greater than 4) requiring oral corticosteroids in the&#xD;
             year prior to randomisation&#xD;
&#xD;
          -  Current or past diagnosis of allergic-bronchopulmonary-aspergillosis&#xD;
&#xD;
          -  Pregnancy and breast feeding&#xD;
&#xD;
          -  Mental impairment or language difficulties that makes informed consent not possible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil C Thomson, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Glasgow</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crosshouse Hospital</name>
      <address>
        <city>Kilmarnock</city>
        <zip>KA2 0BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004 Nov;24(5):822-33. Review.</citation>
    <PMID>15516679</PMID>
  </reference>
  <reference>
    <citation>Richeldi L, Ferrara G, Fabbri LM, Lasserson TJ, Gibson PG. Macrolides for chronic asthma. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002997. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD002997.</citation>
    <PMID>16235309</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2009</study_first_posted>
  <last_update_submitted>October 18, 2011</last_update_submitted>
  <last_update_submitted_qc>October 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Glasgow</investigator_affiliation>
    <investigator_full_name>Euan J Cameron</investigator_full_name>
    <investigator_title>Clinical Research Fellow - Respiratory Medicine</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Smoker</keyword>
  <keyword>Macrolide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

